We are live on ! Find out more
AVNR

AVANIR PHARMACEUTICALS, INC CL A
AVNR

Delisted

AVNR was delisted on the 12th of January, 2015.

100 hedge funds and large institutions have $384M invested in AVANIR PHARMACEUTICALS, INC CL A in 2014 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 31 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $31.2M | Put options by funds: $10.2M

23% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 31

10% more capital invested

Capital invested by funds: $350M → $384M (+$34.1M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1% less funds holding

Funds holding: 101100 (-1)

6% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 18

Holders
100
Holders Change
-1
Holders Change %
-0.99%
% of All Funds
2.89%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
38
Reduced
31
Closed
18
Calls
$31.2M
Puts
$10.2M
Net Calls
+$21.1M
Net Calls Change
+$10.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Prudential Financial
76
Prudential Financial
New Jersey
$54K -$1.91K -500 -3%
PA
77
Profund Advisors
Maryland
$53K +$54.9K +14,400 New
Creative Planning
78
Creative Planning
Kansas
$52K +$1.91K +500 +4%
Comerica Bank
79
Comerica Bank
Texas
$50K
GC
80
Guggenheim Capital
Illinois
$49K -$7.86K -2,062 -13%
VKH
81
Virtu KCG Holdings
New York
$47K -$34.5K -9,061 -42%
AIP
82
Ameritas Investment Partners
Nebraska
$47K
CCMH
83
Cornerstone Capital Management Holdings
New York
$47K +$10.3K +2,700 +27%
Citadel Advisors
84
Citadel Advisors
Florida
$46K -$391K -102,582 -89%
RCM
85
Reynolds Capital Management
Nevada
$46K -$8.77K -2,300 -15%
BBA
86
BLB&B Advisors
Pennsylvania
$46K
N
87
Nuveen
North Carolina
$44K
GA
88
Geneva Advisors
Illinois
$40K -$19.1K -5,000 -31%
OC
89
Oppenheimer & Co
New York
$37K +$38.1K +10,000 New
Teacher Retirement System of Texas
90
Teacher Retirement System of Texas
Texas
$20K +$34 +9 +0.2%
BlackRock
91
BlackRock
New York
$14K
TRCT
92
Tower Research Capital (TRC)
New York
$12K +$12.5K +3,287 New
Ameriprise
93
Ameriprise
Minnesota
$11K +$9.05K +2,375 +579%
PCM
94
Prelude Capital Management
New York
$10K -$56.4K -14,800 -85%
Bank of America
95
Bank of America
North Carolina
$7K -$233K -61,023 -97%
KTC
96
Kistler-Tiffany Companies
Pennsylvania
$6K +$6.57K +1,725 New
RIA
97
Regal Investment Advisors
Michigan
$5K +$5.33K +1,400 New
BBHC
98
Brown Brothers Harriman & Co
New York
$2K
PNC Financial Services Group
99
PNC Financial Services Group
Pennsylvania
$2K +$1.87K +491 New
Manulife (Manufacturers Life Insurance)
100
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$406 -$541 -142 -0.1%

AVNR Hedge Fund Activity: Q1 2014 in Review

100 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in AVANIR PHARMACEUTICALS, INC CL A (AVNR) for Q1 2014, worth a combined $384M — up 9.8% from $350M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of AVNR and 17 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 38 added.

The largest buyer was Fidelity Investments, adding an estimated $12.8M. The largest seller was State Street, cutting an estimated $6.57M.

  • 100 institutional investors held AVANIR PHARMACEUTICALS, INC CL A (AVNR) as of Q1 2014, down from 101 in Q4 2013.
  • Funds reported $384M of AVANIR PHARMACEUTICALS, INC CL A stock for Q1 2014, up 9.8% quarter-over-quarter.
  • 17 funds opened new AVANIR PHARMACEUTICALS, INC CL A positions in Q1 2014 and 18 closed out, a net change of -1 holder.
  • The largest AVANIR PHARMACEUTICALS, INC CL A buyer in Q1 2014 was Fidelity Investments, an estimated $12.8M added.
  • The largest AVANIR PHARMACEUTICALS, INC CL A seller in Q1 2014 was State Street, an estimated $6.57M sold.

Based on aggregated 13F filings for Q1 2014.